Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDLR | P01130 | 15/20 | 0.70 |
| ▸ | BRAF | P15056 | 1/20 | 0.60 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.60 |
| ▸ | CSF1R | P07333 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5897773 | 0.89 | LDLR (0.72) | LDLRBRAFNPC1RAB9A | |
| SCHEMBL5897810 | 0.83 | LDLR (1.00) | LDLRBRAFCSF1RRAB9A | |
| SCHEMBL6781832 | 0.82 | LDLR (1.00) | LDLRBRAFNPC1 | |
| SCHEMBL5897099 | 0.82 | LDLR (0.81) | LDLRBRAFNPC1RAB9A | |
| SCHEMBL6782644 | 0.82 | LDLR (1.00) | LDLRNPC1RAB9A | |
| SCHEMBL6781226 | 0.81 | LDLR (0.84) | LDLRNPC1RAB9APOLB | |
| SCHEMBL6780802 | 0.81 | LDLR (1.00) | LDLRBRAFNPC1RAB9A | |
| SCHEMBL6783138 | 0.81 | LDLR (0.86) | LDLRNPC1RAB9APOLB | |
| SCHEMBL6781265 | 0.81 | LDLR (0.85) | LDLRNPC1RAB9A | |
| SCHEMBL6787743 | 0.80 | LDLR (1.00) | LDLRNPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060700-B2 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | disclosed |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB | 2003-06-05 | — | — | US | disclosed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | disclosed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | IL6, IL6ST, IL2 | LDLR 2806/4885BRAF 1764/4885HSF1 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.